Fine Richard N
Stony Brook University Medical Center, Office of the Dean, Stony Brook, NY 11794-8430, USA.
Nat Clin Pract Nephrol. 2007 Jun;3(6):318-24. doi: 10.1038/ncpneph0502.
Growth retardation frequently accompanies chronic kidney disease in children. Unfortunately, this retardation persists in magnitude despite assiduous therapeutic efforts, adequate dialytic intervention, and successful transplantation. The age of the patient at transplantation, allograft function, and corticosteroid dosage are the major factors that contribute to persistent suboptimal growth following renal transplantation. Recent data indicate that the use of recombinant human growth hormone might efficaciously improve growth velocity in the persistently growth-retarded allograft recipient. Attainment of optimum final adult height is predicated on optimum height at the time of transplantation, persistent optimum allograft function, minimization or avoidance of corticosteroid treatment, and, possibly, use of recombinant human growth hormone, especially to potentially maximize the pubertal growth spurt.
生长发育迟缓在儿童慢性肾病中经常出现。不幸的是，尽管进行了不懈的治疗、充分的透析干预以及成功的移植手术，但这种发育迟缓在程度上仍然持续存在。移植时患者的年龄、同种异体移植肾功能以及皮质类固醇剂量是肾移植后生长持续不理想的主要因素。最近的数据表明，使用重组人生长激素可能有效提高移植后生长持续迟缓患者的生长速度。达到最佳成人终身高取决于移植时的最佳身高、持续的最佳同种异体移植肾功能、尽量减少或避免皮质类固醇治疗，以及可能使用重组人生长激素，特别是为了可能最大限度地促进青春期生长突增。
